News
The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...
Hosted on MSN2mon
Novo Insulin Pen Retreat Risks Drug Access to Kids with Diabetes ...Novo Nordisk, Eli Lilly & Co. and Sanofi dominate the market for insulin products worldwide, while the much-smaller Biocon is a key player in the copycat segment. The global insulin-pen market is ...
Patients with diabetes using a NovoPen Echo from one of the affected batches listed above should call Novo Nordisk at 1-855-419-8827 between 8 a.m. and 6 p.m. Eastern time to get a replacement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results